How Moderna and Merck’s Personalized Melanoma Vaccine Works — and What the Trial Evidence Shows
A cancer vaccine does not prevent cancer in the same way as a childhood vaccine prevents measles. Moderna’s investigational treatment, developed with Merck, is designed for people whose melanoma has already been removed but who remain at high risk of the disease returning.
The treatment is known as intismeran autogene, formerly called mRNA-4157 or V940. It is an individualized neoantigen therapy: each dose is built around mutations found in one patient’s tumor.
The vaccine begins with a tumor sample
After surgery, doctors analyze the tumor’s genetic sequence. Software identifies mutations that may create neoantigens—molecular markers present on cancer cells but absent, or largely absent, from healthy tissue.
The selected targets are encoded in a strand of messenger RNA. Packaged for delivery into cells, the mRNA briefly instructs those cells to produce the chosen cancer markers. The immune system then learns to recognize them and can generate T-cell responses aimed at cancer cells carrying the same mutations.
This approach differs from a conventional vaccine because it is not intended to target one shared pathogen or one universal cancer antigen. It is tailored to the biology of an individual tumor, which makes manufacturing and treatment logistics more complicated.
Why Keytruda is part of the combination
The vaccine is being tested with pembrolizumab, sold as Keytruda. Pembrolizumab blocks the PD-1 pathway, a signal cancers can exploit to weaken T-cell activity. The intended division of labor is straightforward: V940 helps direct immune recognition, while pembrolizumab may help release one of the brakes on the immune response.
The companies’ earlier randomized Phase 2b KEYNOTE-942 study enrolled 157 people with high-risk stage III or IV melanoma after complete tumor removal. In the five-year follow-up reported by Merck, the combination reduced the risk of recurrence or death by 49% compared with Keytruda alone. The result supported continued testing, but the study was relatively small and was not the definitive Phase 3 test required for broad approval.
What a Phase 3 result would still need to answer
The pivotal INTerpath-001 study is designed to compare V940 plus Keytruda with Keytruda alone in roughly 1,089 patients with resected high-risk stage II to IV melanoma. Its main measure is recurrence-free survival. Researchers are also examining distant metastasis-free survival, overall survival, and safety.
A favorable headline result would not make the vaccine immediately available. Regulators would need detailed data, including the size and durability of the benefit, adverse-event rates, manufacturing consistency, and whether the findings apply across important patient subgroups. The treatment remains investigational unless and until regulators authorize it.
Official materials reviewed for this article confirm the long-term Phase 2b findings and the ongoing Phase 3 program. They do not, by themselves, provide a full publicly available Phase 3 data set. That distinction matters: a promising readout can change expectations, but detailed clinical results determine whether the therapy changes melanoma care.